Endogenous mechanisms of neuroprotection
Endogenous mechanisms of neuroprotection
批准号:
7891343
负责人:
HARRIS A GELBARD
金额:
$21.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2010-07-31
关键词:
AIDS Dementia ComplexAIDS neuropathyAntibodiesCell DeathCellsCessation of lifeChronicCognitiveDataDiseaseDominant-Negative MutationEventExposure toFunctional disorderGene ExpressionGenerationsGeneticGoalsHIV-1ImmunoblottingIn VitroIndividualInflammatoryInvestigationJUN geneKnockout MiceLaboratoriesLigandsLightMAPK14 geneMeasuresMediatingMediator of activation proteinMitogen-Activated Protein KinasesN-terminalNerve Growth Factor ReceptorsNeurologicNeurologic DeficitNeuronal DysfunctionNeuronal InjuryNeuronsNeuroprotective AgentsNeurotoxinsPathologyPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphotransferasesProductionProteinsReceptor ActivationRegulationSignal PathwaySignal TransductionSpecificitySynaptic TransmissionT-LymphocyteTdT-Mediated dUTP Nick End Labeling AssayTestingViralVirus Replicationcytokinein vivoinhibitor/antagonistkinase inhibitormitogen-activated protein kinase p38mixed lineage kinase 3monocytemotor deficitneuronal survivalneuroprotectionneurotoxicneurotoxicityneurotrophic factornew therapeutic targetnovelnovel therapeuticspeptidomimeticspreventreceptorresearch studyresponsestress-activated protein kinase 1transcription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
HIV-1 associated neurologic disease is believed to be the result of a chronic inflammatory state, in which
soluble neurotoxic molecules, of both viral and cellular origin, act to cause neuronal injury and dysfunction.
We hypothesize that HIV-1 neurotoxicity is opposed by a number of endogenous pathways and mediators,
which serve to protect neurons. For example, neurotrophins can augment neuronal survival and function
through the activation of specific receptors (Trk receptors) and subsequent initiation of signaling cascades.
We therefore propose to study endogenous neuroprotective pathways that may provide us with new
therapeutic strategies for neuroAIDS. This will be achieved through two specific aims. In Aim 1, experiments
will focus on signaling pathways associated with neurotrophin receptor activation, including analyses of the
neuroprotective effects of inhibitors of mixed lineage kinases (MLK)-3, p38 kinase and c-Jun NH2 terminal
kinases (JNK), as well as peptidomimetic Trk ligands. Effects on the survival and function of neurons
exposed to candidate HIV-1 neurotoxins will be evaluated, as will effects on monocyte/microglial activation.
In the second aim, we will evaluate the cell signaling events that are modulated in response to the inhibition
of MLK-3, using both pharmacological and genetic approaches. These experiments will take advantage of
available dominant negative mutants and MLK-3 knockout mice (to genetically target MLK-3), as well as
extant pharmacologic compounds and new, highly specific MLK-3 blockers that will be developed by our
commercial partner. Collectively, these investigations will identify novel neuroprotective strategies that may
enhance neuronal function and survival in neuroAIDS. Results from these studies will be correlated with
intracellular signaling events that occur in response to drug treatment, in order to identify new therapeutic
targets..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).
-
批准号:10524797
-
项目类别:
-
资助金额:$224.47万
-
财政年份:2022
-
负责人:HARRIS A GELBARD
-
依托单位:
Nanocrystal Quantum Dot Biomimetics of SARS-CoV-2 to Interrogate Neutrophil-Mediated Neuroinflammation at the Blood-Brain Barrier
-
批准号:10510611
-
项目类别:
-
资助金额:$42.35万
-
财政年份:2022
-
负责人:HARRIS A GELBARD
-
依托单位:
Immunoprofiling postoperative delirium during aging and neurodegeneration
-
批准号:10301230
-
项目类别:
-
资助金额:$23.98万
-
财政年份:2021
-
负责人:HARRIS A GELBARD
-
依托单位:
Immunoprofiling postoperative delirium during aging and neurodegeneration
-
批准号:10456947
-
项目类别:
-
资助金额:$19.85万
-
财政年份:2021
-
负责人:HARRIS A GELBARD
-
依托单位:
MLKi Therapy for Cognitive Impairment in Multiple Sclerosis
-
批准号:8904155
-
项目类别:
-
资助金额:$58.67万
-
财政年份:2015
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:9302543
-
项目类别:
-
资助金额:$63.09万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:8893159
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:8736399
-
项目类别:
-
资助金额:$67.39万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:9107504
-
项目类别:
-
资助金额:$63.64万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel HIV Therapies
-
批准号:7891344
-
项目类别:
-
资助金额:$23.43万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Cell and Molecular Core Facility
-
批准号:7891347
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Biostatistics and Data Management
-
批准号:7891348
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Drug Design for the Molecular Target MLK-3
-
批准号:7891346
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease
-
批准号:7891345
-
项目类别:
-
资助金额:$45.84万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Administrative Core
-
批准号:7944986
-
项目类别:
-
资助金额:$14.09万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
The Axon-Oligodendrocyte Precursor Synapse in NeuroAIDS
-
批准号:7495852
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Cell and Molecular Core Facility
-
批准号:7664370
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease
-
批准号:7664368
-
项目类别:
-
资助金额:$30.98万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel HIV Therapies
-
批准号:7664367
-
项目类别:
-
资助金额:$20.93万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Drug Design for the Molecular Target MLK-3
-
批准号:7664369
-
项目类别:
-
资助金额:$10.49万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位: